Danielle Antalffy
Stock Analyst at UBS
(3.67)
# 745
Out of 4,868 analysts
166
Total ratings
50%
Success rate
6.45%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $10 → $8.6 | $5.46 | +57.51% | 6 | May 9, 2025 | |
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $31.57 | +83.72% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $13.34 | +21.81% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $13.87 | +15.36% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $85.73 | +10.81% | 10 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $101.37 | +28.24% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $4.26 | +17.37% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $132.41 | +11.77% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $102.34 | +77.84% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $373.26 | -0.87% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $73.98 | +1.38% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $90.55 | +18.17% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $81.01 | +17.27% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $30.66 | +144.62% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $150.73 | +19.42% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $129.70 | +148.27% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.16 | +4.17% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $29.80 | +44.30% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $509.49 | -45.44% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $20.41 | +120.53% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $301.79 | -7.22% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $19.57 | +4,115.64% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $9.29 | +50.70% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $78.99 | +26.60% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $10.60 | +13.21% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $59.66 | -49.72% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.78 | +7.71% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $168.59 | +63.12% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.27 | +511.62% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.62 | +534.44% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.51 | +493.59% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.16 | +1,193.10% | 1 | Sep 1, 2020 |
Treace Medical Concepts
May 9, 2025
Maintains: Neutral
Price Target: $10 → $8.6
Current: $5.46
Upside: +57.51%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $31.57
Upside: +83.72%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $13.34
Upside: +21.81%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $13.87
Upside: +15.36%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $85.73
Upside: +10.81%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $101.37
Upside: +28.24%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $4.26
Upside: +17.37%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $132.41
Upside: +11.77%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $102.34
Upside: +77.84%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $373.26
Upside: -0.87%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $73.98
Upside: +1.38%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $90.55
Upside: +18.17%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $81.01
Upside: +17.27%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $30.66
Upside: +144.62%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $150.73
Upside: +19.42%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $129.70
Upside: +148.27%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.16
Upside: +4.17%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $29.80
Upside: +44.30%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $509.49
Upside: -45.44%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $20.41
Upside: +120.53%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $301.79
Upside: -7.22%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $19.57
Upside: +4,115.64%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $9.29
Upside: +50.70%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $78.99
Upside: +26.60%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $10.60
Upside: +13.21%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $59.66
Upside: -49.72%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.78
Upside: +7.71%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $168.59
Upside: +63.12%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.27
Upside: +511.62%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.62
Upside: +534.44%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.51
Upside: +493.59%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.16
Upside: +1,193.10%